-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 12, Yifan Pharmaceutical issued an announcement stating that the subsidiary received approval from NMPA regarding the approval of recombinant human growth hormone-Fc fusion protein for injection in accordance with the Drug Clinical Trial Approval Notice, and agreed to carry out children’s growth hormone deficiency and Clinical trials of adult growth hormone deficiency related diseases.
It is reported that F-899 is a long-acting recombinant human growth hormone (Growth Hormone, GH) new molecule designed and developed by the company’s holding subsidiary based on its unique DiKineTM molecular structure platform.